Immunosuppressants/antituberculars Reactions 1680, p176 - 2 Dec 2017 Firth GB, et al. Extraspinal osteoarticular multidrug-resistant tuberculosis in children: A case series. South African Medical Journal 107: 983-986, No. 11, Nov 2017. Available from: URL: - South Africa 803285388 Joint Mycobacterium tuberculosis and development of isoniazid and rifampicin resistance: case report In a retrospective study of 19 children, a 7-year-old boy was described, who developed joint Mycobacterium tuberculosis during treatment with prednisone and methotrexate. Additionally, he developed resistance to isoniazid and rifampicin given for joint tuberculosis [routes, dosages, time to reactions onsets and outcomes not stated]. The boy, who was on chronic prednisone and methotrexate treatment for resistant juvenile dermatomyositis, was admitted with a residual fixed-flexion contracture of his right knee at the age of 12 years. Despite ongoing methotrexate and prednisone treatment, his dermatomyositis was difficult to control. He also had HIV infection. His previous history analysis revealed that at the age of 6 years he had developed a spontaneous abscess just distal to the right knee, which cultured vancomycin-sensitive methicillin-resistant Staphylococcus aureus. This resolved completely after surgical drainage and treatment with vancomycin and further with oral clindamycin. During his seventh year, he developed septic arthritis of the right knee and elbow, which cultured methicillin sensitive Staphylococcus aureus and was successfully treated by surgical drainage and cloxacillin. At the age of seven year, he presented with recurrent swelling and draining sinuses from his right wrist and knee. The blood culture showed presence of M. tuberculosis. As a result, methotrexate was discontinued and he was started on the standard anti-tubercular treatment. One month after the start of the treatment, a favourable improvement of the affected joints was observed. However, a month later, he returned with a recurrent abscess in his right leg. A tissue culture was found to be insoniazid-resistant and rifampicin-sensitive. Therapy was reinitiated with rifampicin, isoniazid, ethionamide and pyrazinamide. Subsequently, clinical improvement was noted again. However, pyrazinamide was discontinued after mild increase in transaminases level. His standard anti-tubercular treatment was stopped following a total duration of 20 months. Two months after the final dose of the triple therapy for mono- resistant tuberculosis, methotrexate was restarted. During his most recent admission, the knee had multiple surgical scars from previous arthrotomies for bacterial septic arthritis and ankylosis at 80° of flexion, and was painful. Pain and globally limited range of motion were also evident in the right hip. Radiographs revealed a periosteal reaction in the mid-shaft of the right femur. A symmetrical loss of the knee joint space with osteopenia and preservation of the physes were also observed. The right hip radiograph showed complete loss of joint space with destruction and an extensive acetabular and femoral bone loss. Laboratory test showed elevated ESR level. He was shifted to the operation theatre for biopsy of the right hip and manipulation of the right knee. Infected tissue and material were evacuated from the hip and sent for microscopy, histology, sensitivity testing and mycobacterial and bacterial culture. Histology showed extensive necrotizing granulomatous inflammation and positive Ziehl-Neelsen staining. The specimen also showed positive tuberculosis culture. Subsequently, PCR testing of the specimen showed resistance to isoniazid and rifampicin. He was treated with amikacin, streptomycin and ciprofloxacin for 24 months. At last follow-up, his hip and knee ankylosis persisted with no pain or inflammation. Author comment: "The relationship of immunity to [multi-drug-resistant tuberculosis] has been established. Case 2 had immunocompromise due to dermatomyositis and its treatment, and the isoniazid-resistant patient was HIV positive." "[T]he immunocompromised state has been associated with an increased prevalence of pulmonary [multi- drug-resistant tuberculosis]." "PCR testing of the specimen was performed after a positive TB culture, and revealed resistance to [isoniazid] and [rifampicin]. 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial